Home / Market News / $ATRC
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Needham Raises Price Target on AtriCure to $70 From $64, Keeps Buy Rating

Nov 4, 2026, 7:08 PM UTC · Primary ticker $ATRC

Needham has increased its price target for AtriCure to $70 from $64, while reiterating a 'Buy' rating. This adjustment follows the company's Q3 2026 financial report, indicating a positive re-evaluation of AtriCure's future performance and market standing.

Needham has raised its price target for AtriCure (ATRC) to $70 from $64 and maintained its 'Buy' rating. This positive revision comes after the company's third-quarter 2026 financial reporting, suggesting that Needham sees continued strength and growth potential for the medical device company. For traders, this indicates a positive sentiment from a reputable analyst firm, which could lead to short-term upward price momentum for ATRC. The long-term implication is a reinforced bullish outlook on the company's fundamentals and market position. A key opportunity for traders is to consider this analyst upgrade as a potential catalyst for further price appreciation, especially if the market reacts favorably to the updated target.

$ATRC positive Price target increase and reaffirmed buy rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.